GH Stock Summary. Guardant Health Inc's stock had its IPO on October 4, 2018, making it an older stock than just 5.21% of US equities in our set. GH's price/sales ratio is 54.31; that's higher than the P/S ratio. 9 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. Their average twelve-month price target is $146.80, predicting that the stock has a possible downside of 6.68%. The high price target for GH is $190.00 and the low price target for GH is $103.00. Find the latest Guardant Health, Inc. (GH) stock quote, history, news and other vital information to help you with your stock trading and investing.
Guardant Health Inc. (NAS) | 2/1/2021 04:00 PM | ||||
hide quote | detailed quote | options chain | |||
Last: | Change: -0.09 | Open: | High: 157.77 | Low: | Volume: 933,999 |
Percent Change: | Yield: n/a | P/E Ratio: | 52 Week Range: 55.90 to 168.52 | ||
2/1/2021 07:55 PM | 155.41 | n/a | 4,533 |
Monday, January 11, 2021
08:37 AM ET
Guardant Health started at buy with $175 stock price target at Stifel Nicolaus MarketWatch
Wednesday, December 02, 2020
06:00 AM ET
DoorDash Is Set to Deliver SoftBank a Big HitThe Wall Street Journal Interactive Edition
Friday, May 15, 2020
08:00 AM ET
SoftBank’s Big Bets Are Hit Hard by CoronavirusThe Wall Street Journal Interactive Edition
Friday, December 13, 2019
07:00 AM ET
Gaurdant Health reiterated as outperform with $130 price target at Leerink MarketWatch
Monday, November 04, 2019
09:18 PM ET
WeWork Isn’t the Only Stumble for SoftBank’s Vision FundThe Wall Street Journal Interactive Edition
Monday, September 23, 2019
08:56 AM ET
What Drove SoftBank’s Vision Fund Up Is Dragging It DownThe Wall Street Journal Interactive Edition
Saturday, September 21, 2019
10:00 AM ET
WeWork Is a Headache for SoftBankThe Wall Street Journal Interactive Edition
Thursday, August 08, 2019
04:50 AM ET
AI Is Hot and SoftBank Is Offering Cash to BurnThe Wall Street Journal Interactive Edition
Wednesday, July 24, 2019
07:07 PM ET
SoftBank Looks to Goldman, Apple for Sequel to $100 Billion Vision FundThe Wall Street Journal Interactive Edition
Friday, May 10, 2019
07:54 AM ET
Guardant Health price target raised to $95 from $83 at SVB Leerink MarketWatch
Wednesday, January 27, 2021
08:05 AM ET
Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer with Similar OutcomesBusinessWire - BZX
Monday, January 18, 2021
03:01 AM ET
Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in EuropeBusinessWire - BZX
Thursday, January 14, 2021
08:06 AM ET
Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal CancerBusinessWire - BZX
Wednesday, December 30, 2020
04:03 PM ET
Guardant Health to Participate in the 39th Annual J.P. Morgan Healthcare ConferenceBusinessWire - BZX
Friday, December 11, 2020
05:00 PM ET
Guardant Health Names Michael Bell as New Chief Financial OfficerBusinessWire - BZX
Monday, December 07, 2020
08:05 AM ET
Guardant Health Presents Data at San Antonio Breast Cancer Symposium Demonstrating Utility of GuardantINFORM™ Real-World Platform in Metastatic Breast CancerBusinessWire - BZX
Monday, November 16, 2020
11:22 PM ET
Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes OfferingBusinessWire - BZX
06:47 AM ET
Guardant Health, Inc. Announces Proposed Convertible Senior Notes OfferingBusinessWire - BZX
Thursday, November 05, 2020
04:49 PM ET
Guardant Health Reports Third Quarter 2020 Financial ResultsBusinessWire - BZX
Friday, October 16, 2020
04:05 PM ET
Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020BusinessWire - BZX